ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2132

Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates

Claire Daien1, Vera Georgescu2, Guillaume Decarriere3, Gael Mouterde3, Cedric Lukas4, Gregoire Mercier2 and JACQUES MOREL5, 1University Hospital, Montpellier, France, 2Department of Medical Information, Montpellier, France, 3Rheumatology, Montpellier, France, 4CHU Montpellier, Montpellier, France, 5Protocole thérapeutique immuno-rhumatologie, Montpellier, France

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, prevention, rheumatoid arthritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of this work was to evaluate the impact of this screening on patient management and hospitalization rates during a 3-year follow-up.

Methods: IRD patients benefiting from the screening program (index date) were identified in the French national health database SNDS and matched to 3 controls on age, sex, IRD and disease duration. The primary endpoint was a composite score assessing the dispensing of comorbidity-preventing drugs (vaccines, anti-platelet treatments, lipid-lowering drugs, anti-osteoporotic drugs) in the year following the index date. Secondary endpoints were cardiologist/pneumologist consultation, all-cause hospitalization rate, hospitalization for fractures, cardiovascular events or infections. Odds ratios (IC95%) were calculated, with multivariate logistic regression adjusted for medical history (hypertension, diabetes, heart failure, CV disease, lung disease, osteoporotic fractures) and medications related to IRD or included in the primary endpoint in the previous year.

Results: 441 patients who had participated in the screening program (exposed) were identified in the national database and matched with 1323 unscreened patients (controls). Of these, 73.9% suffered from rheumatoid arthritis, 18.1% from ankylosing spondylitis and 7.9% from psoriatic arthritis. Exposed patients had significantly less diabetes than controls (4.5 vs. 7.6%) and received significantly less glucocorticoids (36.5 vs. 42.1%), more csDMARDs (56.9 vs. 42.8%) and more bDMARDs (57.4 vs. 32.6%) than controls. The use of drugs evaluated in the primary criteria was more frequent in the year prior to inclusion in the exposed group than in controls (58.4 vs. 45.3%). Exposed patients met the primary endpoint almost twice as often as controls (OR=1.9 [1.5-2.4]). The initiation of preventive medication for comorbidity remained significantly more frequent after adjustment for medical history and previous medication (OR=1.5 [1.1-2.1]). After adjustment for baseline comorbidities, exposed patients consulted significantly more cardiologists or pulmonologists in the year following screening than controls (OR=1.6 [1.2-2.1]). Controls had a three-fold higher risk of all-cause hospitalization (3.1 [2.1-4.6]) at one-year follow-up, which remained significant after adjustment (2.4 [1.5-4.0]). Controls had a significantly higher risk of hospitalization for cardiovascular events (2.1 vs. 0.3%), infections (6.8 vs. 3.6%) and emergency room admissions (20.3 vs. 10.6%) than controls at 2-year follow-up.

Conclusion: The recommendations given during the comorbidity screening program were applied, with an increase in the use of preventive medication for comorbidities and more consultations with specialists. After adjusting for comorbidities and medications at baseline, we observed a decrease in the risk of hospitalization rates, which may reflect the positive impact of carrying out systematic screening for multi-morbidities in IRD patients.


Disclosures: C. Daien: None; V. Georgescu: None; G. Decarriere: None; G. Mouterde: None; C. Lukas: Abbvie, 2, 6, Amgen, 2, 6, Biogen, 2, 6, BMS, 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche Chugai, 2, 6, UCB, 2, 6; G. Mercier: None; J. MOREL: None.

To cite this abstract in AMA style:

Daien C, Georgescu V, Decarriere G, Mouterde G, Lukas C, Mercier G, MOREL J. Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/systematic-screening-for-multimorbidities-leads-to-an-increased-use-of-comorbidity-preventing-medications-and-lower-hospitalization-rates/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systematic-screening-for-multimorbidities-leads-to-an-increased-use-of-comorbidity-preventing-medications-and-lower-hospitalization-rates/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology